Kringle Pharma (TSE:4884) Total Operating Expense: 円985.81 Mil (TTM As of Mar. 2026)


TSE:4884 Kringle Pharma Inc TSE:4884
44 GF Score
Price 円332.00
GF Value 円492.67
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Kringle Pharma Total Operating Expense?

Kringle Pharma TSE:4884 +3.43% 44 Total Operating Expense is 円985.81 Mil as of Mar. 2026. GuruFocus rates TSE:4884 with a GF Score™ of 44/100 and a GF Value™ of 円492.67 (Possible Value Trap). The stock has 5 warning signs investors should review.

Kringle Pharma's Total Operating Expense for the three months ended in Mar. 2026 was 円333.53 Mil. Kringle Pharma's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was 円985.81 Mil.

Kringle Pharma Total Operating Expense Related Terms

Kringle Pharma Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Kringle Pharma's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kringle Pharma Total Operating Expense Chart

Kringle Pharma Annual Data
Trend Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Total Operating Expense
Get a 7-Day Free Trial 576.04 729.58 958.01 897.92 981.67

Kringle Pharma Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 244.55 189.26 218.48 333.53
TSE:4884
44GF Score
Kringle Pharma Inc TSE:4884
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kringle Pharma Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円985.81 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of 円985.81 Mil mean?
Kringle Pharma (TSE:4884) has a Total Operating Expense of 円985.81 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Kringle Pharma and its competitors.
Is Kringle Pharma's Total Operating Expense too high?
Kringle Pharma's current Total Operating Expense is 円985.81 Mil. Overall, Kringle Pharma has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Kringle Pharma's Total Operating Expense compare to VRTX and REGN?
Kringle Pharma's Total Operating Expense of 円985.81 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Kringle Pharma and its competitors. Kringle Pharma's current Total Operating Expense is 円985.81 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kringle Pharma stock overvalued right now?
Based on GuruFocus' analysis, Kringle Pharma (TSE:4884) is currently considered Possible Value Trap. The stock's GF Value™ is 円492.67, compared to a current price of 円332.00 — trading 32.6% below its estimated fair value. The current Total Operating Expense is 円985.81 Mil. Kringle Pharma's overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Kringle Pharma (TSE:4884), the current Total Operating Expense is 円985.81 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kringle Pharma (TSE:4884) Overvalued in 2026?

Based on GuruFocus' analysis, Kringle Pharma stock appears to be undervalued. The current stock price of 円332.00 is trading 32.6% below its estimated GF Value™ of 円492.67. GuruFocus considers Kringle Pharma to be Possible Value Trap.

Key valuation signals for TSE:4884:

  • Total Operating Expense: 円985.81 Mil
  • GF Value™: 円492.67 vs. price of 円332.00 (32.6% below fair value)
  • GF Score™: 44/100 with 5 warning signs

No single metric tells the full story. See the TSE:4884 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kringle Pharma Business Description

Address 7-7-15 Saito asagi, 207 Saito Bio-Incubator, Osaka Prefecture, Ibaraki, JPN, 567-0085
Kringle Pharma Inc is engaged in the research and development of HGF (hepatocyte growth factor) protein as a therapeutic agent for intractable diseases. The Company operates in a single segment, pharmaceutical development.
44GF Score

Get the complete analysis for TSE:4884

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円332.00
Price
円492.67
GF Value